Navigation Links
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
Date:12/2/2009

innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk that that the results of future clinical studies will not correlate or be consistent with the results of the completed studies to date and the risk that the company will experience delays or difficulties in enrolling patients in any planned future clinical studies. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are current
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Glendale, CA (PRWEB) May 21, 2013 ... researchers at the University of California, San Diego for ... of load bearing Gravitic™ MRI (Magnetic Resonance Imaging) with ... is renowned for its continued pursuit of improved healthcare ... , Spinal MRI is an extremely valuable tool for ...
(Date:5/21/2013)... Sunnyvale, CA (PRWEB) May 21, 2013 ... is an 8-week training program starting on June ... to help clinical trial professionals reach the next step ... at Dentons Offices in Palo Alto, and streamed online. ... author of award-winning papers, Clinovo's new “CDISC Standards: Theory ...
(Date:5/20/2013)... ANGELES , May 20, 2013 Today, ... San Francisco , James McGough ... Clinical Psychiatry at the Semel Institute for Neuroscience and ... of Medicine at the University of California Los ... both Child and Adolescent Psychopharmacology and ADHD at UCLA, ...
(Date:5/20/2013)... , Md. and BALTIMORE , ... (BHI), a regional private-public partnership focusing on ... early-stage funding in Central Maryland ... Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for ... National Heart, Lung and Blood Institute ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3Clinovo Launches TechTrainings on CDISC Standards 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... Sept. 13Researchers at Vanderbilt University have developed a new technique ... biological tissue at multiple points simultaneously, a method that could ... grow and change shape. UV lasers are a ... make incisions by vaporizing one point at a time in ...
... FORT WORTH, Texas, Sept. 13, 2011 Healthpoint Biotherapeutics ... Operating Officer, and Robert Bancroft, Executive Vice President, Strategic ... Company, its commercial products and its R&D pipeline at ... is scheduled for the opening day of the conference, ...
... 2011 Microban recently conducted in vitro ... growth on High Consistency Rubber (HCR) silicone, which ... catheters.  Urinary infections are a costly source of ... had limited success in reducing infection rates. The ...
Cached Biology Technology:Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference 2Microban Medical Silver Antimicrobial Technologies for HCR Silicone Achieve 5 Log Reductions in Bacteria Growth and Prevent Biofilm Formation 2
(Date:5/20/2013)... USA New Geology articles posted ... 2013 cover a wide swath of geoscience subdisciplines, ... geophysics, and paleobotany. Locations studied include Siberia; the ... Alpi Apuane, Italy; Ukraine; Mars; and the Southeastern ... 1. Rubies, jadeite, and plate tectonics;, 2. The ...
(Date:5/19/2013)... strain of electricity-producing bacteria that can grow using hydrogen ... as its sole source of carbon. Researchers at ... the 113th General Meeting of the American Society for ... production solely on hydrogen," says Amit Kumar, a researcher ... part of the Lovley Lab Group at the university. ...
(Date:5/18/2013)... The AGA Research Foundation is honored to announce ... in Digestive Cancer, which will support Andrew D. Rhim, ... University of Pennsylvania, Philadelphia, as he furthers his research ... and cancer progression. , "The AGA Research Foundation is ... distinguished clinicians and AGA Legacy Society members," said Nicholas ...
Breaking Biology News(10 mins):New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11AGA Research Foundation grant furthers digestive cancer research 2
... Dec. 2, 2008 Presbycusis, or age-related hearing loss, ... why do some people lose their hearing as they get ... The answer may be in a study ... Advance access is available online at http://hmg.oxfordjournals.org/papbyrecent.dtl . ...
... Mercury levels in fish are prompting widespread consumption advisories ... to eat. Now researchers at North Carolina State University ... regulators around the country predict which areas are likely ... breakthrough that should help officials address public uncertainty by ...
... University,s Woods Institute for the Environment, The Nature ... a two-year, $1.97 million grant from the Gordon ... program for mapping and evaluating the economic benefits ... InVEST (Integrated Valuation of Ecosystem Services and Tradeoffs), ...
Cached Biology News:House Ear Institute, TGen and Belgian researchers identify gene in age-related hearing loss 2New model predicts hot spots for mercury in fish 2Natural Capital Project to develop conservation software 2
... IgG FITC is used as the ... on tissues or culture cells where ... rabbits. It is highly recommended that ... the primary antibody, be included in ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Request Info...
HAS1 (C-14)...
Biology Products: